Publication · Feb 2026
Science
Explore conditions, clinical trials, and the latest research.
These pages contain non-exhaustive scientific information about uses of products that have not yet been approved by regulatory authorities, as their efficacy and safety for these uses have not yet been established. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
Publication · Feb 2026
Impact of acoramidis on clinical stability: ATTRibute-CM (Bayer/BridgeBio)
Publication · Dec 2025
A plain language review of the ATTRibute-CM study from NEJM
Presentation · Nov 2025 · PDF
Acoramidis -AHA 2025- Vutisiran HCRU and discontinuation
Presentation · Nov 2025 · PDF
Acoramidis -AHA 2025- D28 sTTR association with CVMCVH
Presentation · Nov 2025 · PDF
Acoramidis -AHA 2025- Atrial fibrillation at baseline and clinical outcomes
Presentation · Nov 2025 · PDF
Acoramidis -AHA 2025- ACM and ACMCVH Subgroup Analysis
Presentation · Nov 2025 · PDF
Acoramidis-AHA 2025- Variant ACM and First CVH
Presentation · Nov 2025 · PDF
Acoramidis -AHA 2025- p.V142I (V122I) ACM analysis
Presentation · Nov 2025 · PDF